Mangoceuticals, Inc. (MGRX)
NASDAQ: MGRX · Real-Time Price · USD
0.3380
-0.0220 (-6.11%)
At close: Apr 2, 2026, 4:00 PM EDT
0.3500
+0.0120 (3.55%)
After-hours: Apr 2, 2026, 7:53 PM EDT
Mangoceuticals Revenue
Mangoceuticals had revenue of $84.25K in the quarter ending September 30, 2025, a decrease of -36.83%. This brings the company's revenue in the last twelve months to $466.91K, down -38.16% year-over-year. In the year 2024, Mangoceuticals had annual revenue of $615.87K, down -15.81%.
Revenue (ttm)
$466.91K
Revenue Growth
-38.16%
P/S Ratio
11.41
Revenue / Employee
$152,007
Employees
3
Market Cap
5.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 615.87K | -115.62K | -15.81% |
| Dec 31, 2023 | 731.49K | 722.55K | 8,083.16% |
| Dec 31, 2022 | 8.94K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMGRX News
- 12 days ago - Mangoceuticals Stock Doubles After Texas Lawsuit - Benzinga
- 18 days ago - Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. - GlobeNewsWire
- 4 weeks ago - Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds - GlobeNewsWire
- 5 weeks ago - Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study - GlobeNewsWire
- 6 weeks ago - Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally? - Benzinga
- 6 weeks ago - Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model - Benzinga
- 6 weeks ago - MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program - GlobeNewsWire
- 3 months ago - Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements - GlobeNewsWire